- The first presentation of efficacy and safety results from a Phase IIb study of subcutaneous (SC) clazakizumab, an investigational anti-IL-6 monoclonal antibody, in adults with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to methotrexate. Bristol-Myers Squibb has exclusive worldwide rights to develop and commercialize clazakizumab for all indications outside of cancer under a collaboration agreement with its discoverer, Alder Biopharmaceuticals.
- Results from the two-year AMPLE trial of Orencia ® SC (abatacept) and Humira ® (adalimumab) in biologic-naive RA patients, including efficacy, safety and patient-reported outcomes data.
- More than 10 health economics and outcomes research presentations that add to the collective understanding of real-world use of RA medications and the costs associated with treatment.
|A Phase IIb Study Of The Efficacy and Safety Of Subcutaneous Clazakizumab (anti-IL-6 monoclonal antibody) With Or Without Methotrexate In Adults With Moderate-To-Severe Active Rheumatoid Arthritis and An Inadequate Response To Methotrexate||Oral Presentation October 28 2:30 - 4 pm|
|Anti-IL-6 Antibody Clazakizumab Is More Potent Than Tocilizumab In Blocking In Vitro and Ex Vivo IL-6-Induced Functions||October 29|
|Head-To-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in RA: Two Year Results from the AMPLE Study||October 29|
|2-Year Results from the AMPLE (Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: Changes in Patient-Reported Outcomes in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis||October 27|
|Effects of SC Abatacept or Adalimumab on Remission and Associated Changes in Physical Function and Radiographic Outcomes: Two Year Results from the AMPLE Trial||October 27|
|Abatacept or anti-TNF monoclonal antibodies: Efficacy and safety comparisons||October 29|
|Antibody response to pneumococcal and influenza vaccination in patients with RA receiving subcutaneous abatacept||October 27|
|Adherence to the Recommended Dosing Regimen of Abatacept in the Real-world Setting in the ACTION Study: Is There a Dose-creep in Overweight Patients?||October 28|
|Gene expression in whole blood predicts the abatacept-methotrexate combination responsiveness in rheumatoid arthritis: preliminary results||October 29|
|Abatacept is highly effective at inhibiting T cell priming and induces a unique transcriptional profile in CD4+ T cells||October 27|
|Pilot Study of Abatacept in Patients with Refractory Autoimmune Chronic Urticaria||October 29|
|Musculoskeletal Hospital Admissions Among Patients Treated For Rheumatoid Arthritis Between 1999 and 2010 Compared With The General Population In The Netherlands||October 27|
|Evaluation Of Hospitalizations and Costs In Patients With Rheumatoid Arthritis In United States Medicare Population||October 28|
|Analysis Of Non-Steroidal Anti-Inflammatory Drug Burden Among Rheumatoid Arthritis Patients Using The Dougados Algorithm||October 27|
|Biologic Switching Rates among Patients with Rheumatoid Arthritis in Medicare||October 29|
|Rates of Switching and Healthcare Costs Associated with Switching Biologic Disease-modifying Antirheumatic Drugs in a Commercial Population: Evidence from Real-world Observational Studies||October 28|
|Outcomes of patients with rheumatoid arthritis and comorbid hyperlipidaemia||October 27|
|Prevalence of Systemic Lupus Erythematosus and Lupus Nephritis in the United States: Analysis of Commercial and Public Insurance Billing Data||October 28|
|Coronary endothelial dysfunction directly measured by N13 Positron Emission Tomography (PET) is detected in established Rheumatoid Arthritis (RA), but not early RA||October 27|
|Assessing Validity Of Low Field Magnetic Resonance Imaging (MRI) for Joint Inflammation and Damage In Wrist/Hand Rheumatoid Arthritis (RA) - A Systematic Literature Review (SLR)||October 29|